AGEN vs. STRO, OYST, PSTX, ADAP, ATHA, BCRX, MNKD, INVA, IRWD, and OPK
Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Sutro Biopharma (STRO), Oyster Point Pharma (OYST), Poseida Therapeutics (PSTX), Adaptimmune Therapeutics (ADAP), Athira Pharma (ATHA), BioCryst Pharmaceuticals (BCRX), MannKind (MNKD), Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), and OPKO Health (OPK). These companies are all part of the "medical" sector.
Agenus (NASDAQ:AGEN) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability, community ranking and media sentiment.
In the previous week, Sutro Biopharma had 2 more articles in the media than Agenus. MarketBeat recorded 3 mentions for Sutro Biopharma and 1 mentions for Agenus. Sutro Biopharma's average media sentiment score of 0.45 beat Agenus' score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the news media.
Sutro Biopharma has a net margin of -74.61% compared to Agenus' net margin of -154.88%. Agenus' return on equity of 0.00% beat Sutro Biopharma's return on equity.
Agenus presently has a consensus target price of $70.00, indicating a potential upside of 321.69%. Sutro Biopharma has a consensus target price of $12.50, indicating a potential upside of 236.93%. Given Agenus' higher probable upside, equities analysts clearly believe Agenus is more favorable than Sutro Biopharma.
61.5% of Agenus shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 4.6% of Agenus shares are owned by insiders. Comparatively, 5.9% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Agenus has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Sutro Biopharma has lower revenue, but higher earnings than Agenus. Sutro Biopharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.
Agenus received 342 more outperform votes than Sutro Biopharma when rated by MarketBeat users. Likewise, 70.14% of users gave Agenus an outperform vote while only 64.74% of users gave Sutro Biopharma an outperform vote.
Summary
Sutro Biopharma beats Agenus on 9 of the 17 factors compared between the two stocks.
Get Agenus News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
